Table 2 Response rates prior to start of maintenance therapy.

From: Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

 

BTZ cohort n = 134

LEN cohort n = 179

p

Single categories

  

<0.001

 CR

41 (31%)

38 (21%)

 nCR

11 (8%)

55 (31%)

 VGPR

31 (23%)

34 (19%)

 PR

50 (37%)

42 (23%)

 MR

1 (1%)

9 (5%)

 SD

0 (0%)

1 (1%)

Combined categories

 CR/nCR

52 (39%)

93 (52%)

0.02

 ≥VGPR

83 (62%)

127 (71%)

0.11

 PR/MR/SD

51 (38%)

52 (29%)

0.11

  1. Data are n (%).
  2. CR complete response, nCR near CR, VGPR very good partial response, PR partial response, MR minimal response, SD stable disease.
Back to article page